Eisai Co., Ltd.
Regarding the Sales Revenue (Preliminary) of Anti-Amyloid β Protofibril Antibody “Leqembi®”
The cumulative sales revenue of the anti-amyloid β protofibril antibody “Leqembi®” for fiscal year 2025 was JPY 88 billion, with JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China.
Key Figures
- Leqembi® cumulative sales revenue for fiscal year 2025: JPY 88 billion (unaudited preliminary figures)
- U.S. sales revenue: JPY 44.6 billion
- Japan sales revenue: JPY 24.4 billion
AI要約
Overview of Sales Revenue
Eisai Co., Ltd. announced preliminary cumulative sales revenue for the anti-amyloid β protofibril antibody “Leqembi®” (generic name: lecanemab) for fiscal year 2025 (April 1, 2025, to March 31, 2026). Global total sales reached JPY 88 billion, with major country breakdowns of JPY 44.6 billion in the U.S., JPY 24.4 billion in Japan, and JPY 12.4 billion in China. These figures are preliminary and unaudited.
Future Disclosure Plans and Business Framework
Detailed sales revenue information and fiscal year 2025 performance will be disclosed at the financial results announcement scheduled for May 15, 2026. Eisai leads the global development and regulatory submission of lecanemab, with Eisai and Biogen jointly managing commercialization and promotion.
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
